Tags : ixekizumab

Biotech

Eli Lilly to Present Data of Taltz (ixekizumab) for Patients

Shots: Eli Lilly shared new results from a subgroup analysis of the P-IIIb/IV, 52-wks. SPIRIT-H2H study assessing Taltz vs Humira (adalimumab) in biologic-naïve patients with active PsA with 1EPs as ACR50 & PASI 100 @24wks. The study compares Taltz and Humira in subgroups of patients on monothx./ concomitant MTX/ concomitant MTX along with csDMARD including […]Read More

Biotech

Eli Lilly Reports Results of Taltz (ixekizumab) in 5 Years

Shots: The P-III study results involves assessing of Taltz in patients with moderate to severe plaque psoriasis for 5yrs.in addition to an extension study UNCOVER-1 Collective results: 90%+ maintained skin clearance as measured by PASI 75; @264wks. PASI 75 (94.3); PASI 90 (81.8%); PASI 100 (46.6%), presented at WCD with additional data of UNCOVER-3 study […]Read More

Biotech

Lilly Reports Results of Taltz (ixekizumab) in P-III COAST-X Study

Shots: The P-III COAST-X study involves assessing of Taltz (ixekizumab) vs PBO in patients with non-radiographic axial spondyloarthritis (nr-axSpA) who are biologic disease-modifying anti-rheumatic drug (bDMARD) naive for 52wks. The P-III COAST-X study results:  @16 & 52wks. met its 1Eps & 2Eps; improvement in the signs and symptoms of nr-axSpA; improvement in ASDAS & BASDAI; […]Read More